Are These Stocks Undervalued? Discovery Laboratories Inc (DSCO), Energy Recovery Inc (ERII) and Achaogen Inc (AKAO)

Posted by admin April 2, 2015 0 Comment 1294 views

New York, NY – GDP INSIDER  –  04/02/2015.

This article discusses three companies: Discovery Laboratories Inc (NASDAQ:DSCO), Energy Recovery Inc (NASDAQ:ERII) and Achaogen Inc (NASDAQ:AKAO)

Discovery Laboratories Inc (NASDAQ:DSCO) reversed  its recent decline yesterday with the stock gaining 0.84% or $0.01 to close at $1.20 on active trading of 0.651 million shares, compared to its three month average trading volume of 0.384 million. The manufacturer and developer of products for infants should be rising more rapidly, after strong upward revisions in its forecasts. Analysts have projected that its earnings could increase by as much as 20% in the current year, but the stock is still down 25.46% over the last month. With RSI now at 34.23 it is definitely worth a speculative buy.

Is Discovery Laboratories Inc A Good Medium Term Investment? Take A Look At The Technical Indicators With Free DSCO Analysis.

Energy Recovery Inc (NASDAQ:ERII) posted strong gains yesterday with the stock climbing 11.20% or $0.29 to close at $2.88 on very active trading of 0.779 million shares, when compared to its three month average trading volume of 0.268 million. The developer and manufacturer of energy recovery devices has been falling of late and saw the boost after it announced that it had been commissioned for its first IsoGen system for gas processing by the Saudi Arabian Oil Company, its largest new project to date. With the stock just crossing a bullish MACD crossover, it is a good time to buy.

Can Energy Recovery Inc Maintain An Upward Trend? Read Our Free ERII Analysis To Get A Better Idea.

Achaogen Inc (NASDAQ:AKAO) declined again yesterday with the stock falling another 18.03% or $1.76 to close at $8.00 with more than 0.794 million shares changing hands, compared to its three month average trading volume of 0.087 million. The clinical stage biopharmaceutical company specialized in novel antibacterials saw the declines after it announced that it was considering an additional phase III trial for its experimental drug plazomicin. Achaogen Inc hopes that with positive data from the extra research, it can successfully complete a new drug application potentially making it a long term investment prospect.

Do Achaogen Inc’s Fundamentals Support A Reverse In Fortune? Click Here For Free AKAO Analysis.

About UltimateStockAlerts provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.

UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure:  UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit website, for complete risks and disclosures.

Write Your Comment